 LEXINGTON, Mass., Oct. 12, 2021 GLOBE NEWSWIRE -- Kaleido Biosciences, Inc. Nasdaq: KLDO, a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis, today announced that CEO Dan Menichella will present a company overview at the Jefferies Virtual Next Generation IBD Therapeutics Summit at 1:45PM ET on Tuesday, October 19. 